Oncobiologics Launches CDMO Biz; Forms First Contract
By

Oncobiologics, a Cranbury, New Jersey-based biopharmaceutical company developing monoclonal antibody (mAb) biosimilars, has launched a contract development and manufacturing (CDMO) business. It further formed a master services agreement (MSA) with Sonnet BioTherapeutics, a Cranbury, New Jersey-based development-stage biopharmaceutical company, as its first contract for its CDMO business. 

The terms of the MSA were not disclosed, but the MSA instructs Oncobiologics to provide CDMO services for up to four drug-product candidates over the next three years.

The CDMO business is based on Oncobiologics’ BioSymphony Platform for developing mAbs. Oncobiologics’ BioSymphony Platform is used to develop mAb therapeutics for both in-house programs as well as external CDMO services.

Source: Oncobiologics

Leave a Reply

Your email address will not be published.